STOCK TITAN

Surmodics Announces Successful First Patient Use of Sublime™ Radial Access Microcatheter Designed for the Periphery

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Surmodics, Inc. (NASDAQ:SRDX) has introduced the industry’s first suite of torqueable peripheral microcatheters through its Sublime Radial Access Platform. Dr. Ankur Lodha and Dr. Pradeep Nair were the first physicians to utilize the Sublime™ microcatheter, which is currently in limited market evaluation, with a full launch expected in FY 2024. This new line includes microcatheters designed for superior navigation of complex lesions in both transradial and transfemoral procedures. Notably, these microcatheters boast features like Pristyne™ hydrophilic coating and dual stainless steel locked-braid layers for enhanced torque control. The company’s commitment to expanding its endovascular devices portfolio aims to address unmet clinical needs and improve patient outcomes in peripheral artery disease.

Positive
  • Launch of the world’s first suite of torqueable peripheral microcatheters under the Sublime brand.
  • Successful initial use by leading interventional cardiologists indicating high performance in treating peripheral arterial disease.
  • Potential to improve patient outcomes and enhance the adoption of radial access procedures.
  • Plans for a full product launch in FY 2024, expanding the company’s market potential.
Negative
  • Limited market evaluation period may hinder immediate revenue generation.
  • Dependence on the upcoming full launch for significant market impact.

Sublime Radial Access Platform to include the industry’s first suite of torqueable peripheral microcatheters, designed for navigating tortuosity and crossing complex lesions and available for both transradial and transfemoral procedures

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Ankur Lodha, Lafayette, La., and Dr. Pradeep Nair, Houma, La., are the first physicians to use the company’s Sublime™ radial access microcatheter. Drs. Lodha and Nair are interventional cardiologists at the Cardiovascular Institute of the South.

The Sublime microcatheter is in limited market evaluation. The full suite of Sublime microcatheters will be launched in FY 2024. The Sublime portfolio will include the industry’s first suite of 0.014”, 0.018”, and 0.035” high-performance peripheral microcatheters.

“For peripheral as well as coronary interventions, radial access is safer than femoral access and much preferred by patients,” said Dr. Lodha. “I’m pleased to report that the Sublime microcatheter performed exceptionally well during our first uses of the device in treating peripheral arterial disease.”

“The lack of long-length, high-performance catheters for peripheral procedures has slowed adoption of radial access for treatment of lower extremity artery disease,” added Dr. Nair. “Sublime microcatheters will fill a major gap in the peripheral-intervention toolkit, including for procedures from access sites other than the wrist.”

Available in five lengths from 65 to 200 cm and compatible with 0.014”, 0.018”, and 0.035” guidewires, the Sublime microcatheters feature Surmodics’ best-in-class Pristyne™ hydrophilic coating for superb lubricity to optimize device trackability through vessel tortuosity. The device’s dual stainless steel, locked-braid layers work in unison to optimize torque control, push transmission, and deliverability to distal target lesions. The microcatheters are available in straight or angled tip configurations to access all types of peripheral vessels within their indicated size range. The Sublime 0.014” and 0.018” microcatheters can be telescoped through the 0.035” Sublime microcatheter to provide additional back up support when navigating extreme tortuosity or heavily stenosed lesions. This combination of optimized torque and stackability is designed to bring a new level of deliverability and crossing performance to the peripheral vascular space.

“This successful first use of our Sublime microcatheters is a major milestone, not only for Surmodics, but for the countless patients who stand to benefit from peripheral arterial treatment,” said Gary Maharaj, President and CEO of Surmodics, Inc. “For years, torqueable microcatheters have enabled coronary operators to overcome the most extreme challenges presented by complex arterial disease. We are pleased to bring this industry-first capability to peripheral interventions.”

The new line of Surmodics’ Sublime microcatheters, along with Surmodics’ guide sheaths and 0.014” and 0.018” RX PTA dilation catheters, round out a complete line of Sublime Radial Access Platform products. These products represent Surmodics’ commitment to leading the radial revolution with its expanding portfolio of endovascular devices purpose-designed to facilitate the treatment of above- or below-the-knee peripheral lesions via a transradial approach.

About Surmodics, Inc.

Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development and manufacturing capabilities. The company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about the anticipated launch of the full suite of Sublime microcatheters and the company’s growth strategy, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the results from current LMEs, the availability of products for commercial launch, and the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10‑K for the fiscal year ended September 30, 2022, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Surmodics Investor Inquiries:

Jack Powell, Investor Relations

ir@surmodics.com



Surmodics Public Relations Inquiries

pr@surmodics.com

Source: Surmodics, Inc.

FAQ

What is Surmodics' latest product in the stock symbol SRDX?

Surmodics' latest product is the Sublime™ radial access microcatheter, which is the first of its kind in the industry.

When will the Sublime microcatheters be fully launched?

The full suite of Sublime microcatheters is expected to launch in FY 2024.

What medical procedure does the Sublime microcatheter aim to improve?

The Sublime microcatheter is designed to enhance procedures for treating peripheral arterial disease.

Who were the first physicians to use the Sublime microcatheter?

The first physicians to use the Sublime microcatheter were Dr. Ankur Lodha and Dr. Pradeep Nair.

What are the key features of the Sublime microcatheters?

Key features include Pristyne™ hydrophilic coating and dual stainless steel locked-braid layers for optimized torque control.

Surmodics, Inc.

NASDAQ:SRDX

SRDX Rankings

SRDX Latest News

SRDX Stock Data

535.73M
14.27M
3.8%
89.75%
2.23%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
EDEN PRAIRIE